AYTU Fundamental Analysis - AYTU BIOPHARMA INC

Fundamental Rating

AYTU gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of AYTU while its profitability can be described as average. AYTU has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AYTU has reported negative net income.

AYTU had a negative operating cash flow in the past year.

AYTU had negative earnings in each of the past 5 years.

In the past 5 years AYTU always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of AYTU (1.32%) is better than 82.90% of its industry peers.

With an excellent Return On Equity value of 4.70%, AYTU belongs to the best of the industry, outperforming 84.97% of the companies in the same industry.

The Return On Invested Capital of AYTU (0.46%) is better than 77.20% of its industry peers.

		Industry Rank	Sector Rank
ROA	1.32%
ROE	4.7%
ROIC	0.46%

ROA(3y)-35%

ROA(5y)-27.17%

ROE(3y)-112.19%

ROE(5y)-78.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin of AYTU (2.37%) is better than 83.42% of its industry peers.

Looking at the Operating Margin, with a value of 0.53%, AYTU is in the better half of the industry, outperforming 77.20% of the companies in the same industry.

AYTU has a Gross Margin of 68.59%. This is in the better half of the industry: AYTU outperforms 76.17% of its industry peers.

AYTU's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	0.53%
PM (TTM)	2.37%
GM	68.59%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.82%

GM growth 5Y-0.72%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AYTU is destroying value.

AYTU has more shares outstanding than it did 1 year ago.

The number of shares outstanding for AYTU has been increased compared to 5 years ago.

AYTU has a worse debt/assets ratio than last year.

2.2 Solvency

AYTU has an Altman-Z score of -2.82. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.

AYTU has a Altman-Z score (-2.82) which is in line with its industry peers.

AYTU has a Debt/Equity ratio of 0.56. This is a neutral value indicating AYTU is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.56, AYTU is doing worse than 63.21% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.56
Debt/FCF	N/A
Altman-Z	-2.82

ROIC/WACC0.03

WACC16.49%

2.3 Liquidity

A Current Ratio of 1.03 indicates that AYTU should not have too much problems paying its short term obligations.

AYTU has a worse Current ratio (1.03) than 82.90% of its industry peers.

AYTU has a Quick Ratio of 1.03. This is a bad value and indicates that AYTU is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.87, AYTU is not doing good in the industry: 79.79% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.03
Quick Ratio	0.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.03% over the past year.

The Revenue for AYTU has decreased by -26.17% in the past year. This is quite bad

The Revenue has been growing by 61.82% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)57.03%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%140.38%

Revenue 1Y (TTM)-26.17%

Revenue growth 3Y7.28%

Revenue growth 5Y61.82%

Sales Q2Q%2.55%

3.2 Future

Based on estimates for the next years, AYTU will show a very strong growth in Earnings Per Share. The EPS will grow by 30.75% on average per year.

AYTU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.72% yearly.

EPS Next Y123.54%

EPS Next 2Y42.55%

EPS Next 3Y30.75%

EPS Next 5YN/A

Revenue Next Year-12.88%

Revenue Next 2Y-2.69%

Revenue Next 3Y6.76%

Revenue Next 5Y9.72%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AYTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Based on the Price/Forward Earnings ratio of 23.42, the valuation of AYTU can be described as rather expensive.

72.02% of the companies in the same industry are more expensive than AYTU, based on the Price/Forward Earnings ratio.

The average S&P500 Price/Forward Earnings ratio is at 35.58. AYTU is valued slightly cheaper when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	23.42

4.2 Price Multiples

99.48% of the companies in the same industry are more expensive than AYTU, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	1.96

4.3 Compensation for Growth

AYTU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

AYTU's earnings are expected to grow with 30.75% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.55%

EPS Next 3Y30.75%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AYTU does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AYTU BIOPHARMA INC

NASDAQ:AYTU (7/14/2025, 8:24:27 PM)

After market: 2.19 +0.04 (+1.86%)

2.15

-0.03 (-1.38%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-14 2025-05-14/amc

Earnings (Next)09-24 2025-09-24/amc

Inst Owners30.46%

Inst Owner Change0%

Ins Owners2.6%

Ins Owner Change0.64%

Market Cap19.31M

Analysts82.86

Price Target9.18 (326.98%)

Short Float %6%

Short Ratio0.28

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)115.04%

Min EPS beat(2)8.96%

Max EPS beat(2)221.11%

EPS beat(4)3

Avg EPS beat(4)40.1%

Min EPS beat(4)-78.65%

Max EPS beat(4)221.11%

EPS beat(8)6

Avg EPS beat(8)-402.91%

EPS beat(12)8

Avg EPS beat(12)-280.54%

EPS beat(16)9

Avg EPS beat(16)-239.81%

Revenue beat(2)2

Avg Revenue beat(2)16.96%

Min Revenue beat(2)2.24%

Max Revenue beat(2)31.67%

Revenue beat(4)3

Avg Revenue beat(4)8.11%

Min Revenue beat(4)-3.7%

Max Revenue beat(4)31.67%

Revenue beat(8)6

Avg Revenue beat(8)3.06%

Revenue beat(12)8

Avg Revenue beat(12)1.57%

Revenue beat(16)9

Avg Revenue beat(16)0.32%

PT rev (1m)12.5%

PT rev (3m)12.5%

EPS NQ rev (1m)-105.66%

EPS NQ rev (3m)-105.66%

EPS NY rev (1m)-8.33%

EPS NY rev (3m)-8.33%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-4.69%

Revenue NY rev (1m)0%

Revenue NY rev (3m)5.59%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	23.42
P/S	0.28
P/FCF	N/A
P/OCF	N/A
P/B	0.55
P/tB	N/A
EV/EBITDA	1.96

EPS(TTM)-1.13

EYN/A

EPS(NY)0.09

Fwd EY4.27%

FCF(TTM)-0.64

FCFYN/A

OCF(TTM)-0.62

OCFYN/A

SpS7.71

BVpS3.89

TBVpS-1.54

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	1.32%
ROE	4.7%
ROCE	0.69%
ROIC	0.46%
ROICexc	0.64%
ROICexgc	N/A
OM	0.53%
PM (TTM)	2.37%
GM	68.59%
FCFM	N/A

ROA(3y)-35%

ROA(5y)-27.17%

ROE(3y)-112.19%

ROE(5y)-78.65%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.82%

GM growth 5Y-0.72%

F-Score4

Asset Turnover0.56

Health

		Industry Rank	Sector Rank
Debt/Equity	0.56
Debt/FCF	N/A
Debt/EBITDA	3.06
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	0.13
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.03
Quick Ratio	0.87
Altman-Z	-2.82

F-Score4

WACC16.49%

ROIC/WACC0.03

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)57.03%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%140.38%

EPS Next Y123.54%

EPS Next 2Y42.55%

EPS Next 3Y30.75%

EPS Next 5YN/A

Revenue 1Y (TTM)-26.17%

Revenue growth 3Y7.28%

Revenue growth 5Y61.82%

Sales Q2Q%2.55%

Revenue Next Year-12.88%

Revenue Next 2Y-2.69%

Revenue Next 3Y6.76%

Revenue Next 5Y9.72%

EBIT growth 1Y-80.87%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year590.61%

EBIT Next 3Y126.46%

EBIT Next 5YN/A

FCF growth 1Y73.41%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y74.38%

OCF growth 3YN/A

OCF growth 5YN/A

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens